Detalhe da pesquisa
1.
Lenalidomide monotherapy in chemotherapy-naive, castration-resistant prostate cancer patients: final results of a phase II study.
Clin Genitourin Cancer
; 12(1): 27-32, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24238760
2.
Erlotinib has moderate single-agent activity in chemotherapy-naïve castration-resistant prostate cancer: final results of a phase II trial.
Urology
; 74(3): 665-71, 2009 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-19616281